PGAM2
Basic information
Region (hg38): 7:44062727-44065567
Links
Phenotypes
GenCC
Source:
- glycogen storage disease due to phosphoglycerate mutase deficiency (Strong), mode of inheritance: AR
- glycogen storage disease due to phosphoglycerate mutase deficiency (Strong), mode of inheritance: AR
- glycogen storage disease due to phosphoglycerate mutase deficiency (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Glycogen storage disease X | AR | Renal | Preventive measures to reduce the chance of severe sequelae can be beneficial, as individuals can present with exercise intolerance, and renal failure has been described | Biochemical; Musculoskeletal; Renal | 6283419; 6262916; 6308514; 8447317; 10545043; 19273759 |
ClinVar
This is a list of variants' phenotypes submitted to
- Glycogen storage disease type X (6 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PGAM2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 33 | 37 | ||||
missense | 81 | 82 | ||||
nonsense | 5 | |||||
start loss | 0 | |||||
frameshift | 4 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 4 | 4 | 8 | |||
non coding | 11 | |||||
Total | 6 | 3 | 86 | 42 | 4 |
Highest pathogenic variant AF is 0.0000133
Variants in PGAM2
This is a list of pathogenic ClinVar variants found in the PGAM2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
7-44062729-T-C | Glycogen storage disease type X | Uncertain significance (Jan 12, 2018) | ||
7-44062771-G-T | Glycogen storage disease type X | Uncertain significance (Jun 27, 2023) | ||
7-44062800-G-A | Glycogen storage disease type X • PGAM2-related disorder | Conflicting classifications of pathogenicity (Jan 23, 2025) | ||
7-44062806-C-G | Glycogen storage disease type X | Likely benign (Dec 24, 2021) | ||
7-44062807-C-T | Glycogen storage disease type X • Inborn genetic diseases | Uncertain significance (Sep 26, 2023) | ||
7-44062808-G-C | Inborn genetic diseases | Uncertain significance (Nov 04, 2022) | ||
7-44062812-C-T | Glycogen storage disease type X | Likely benign (Jul 31, 2024) | ||
7-44062813-G-A | Glycogen storage disease type X • Inborn genetic diseases | Uncertain significance (Jul 14, 2023) | ||
7-44062819-T-G | Glycogen storage disease type X • PGAM2-related disorder | Conflicting classifications of pathogenicity (Jan 18, 2025) | ||
7-44062842-C-T | Glycogen storage disease type X | Likely benign (Oct 31, 2022) | ||
7-44062853-T-G | Glycogen storage disease type X • Inborn genetic diseases | Uncertain significance (May 23, 2023) | ||
7-44062882-G-T | Inborn genetic diseases | Uncertain significance (Mar 05, 2024) | ||
7-44062889-C-T | Rhabdomyolysis | Likely pathogenic (Aug 05, 2017) | ||
7-44062890-C-T | Glycogen storage disease type X | Likely benign (Mar 19, 2024) | ||
7-44062891-G-A | Uncertain significance (Sep 15, 2023) | |||
7-44062915-G-A | Glycogen storage disease type X | Uncertain significance (Sep 01, 2021) | ||
7-44062933-A-G | Glycogen storage disease type X | Benign/Likely benign (Jan 20, 2025) | ||
7-44062937-C-T | Glycogen storage disease type X | Uncertain significance (Apr 05, 2023) | ||
7-44062938-G-A | Glycogen storage disease type X | Likely benign (Feb 02, 2024) | ||
7-44062947-A-G | Glycogen storage disease type X | Likely benign (Oct 01, 2022) | ||
7-44064620-A-G | Benign (Jun 29, 2018) | |||
7-44064815-C-T | Glycogen storage disease type X | Likely benign (Feb 06, 2023) | ||
7-44064821-G-A | Glycogen storage disease type X | Likely benign (Jun 22, 2024) | ||
7-44064829-C-A | Glycogen storage disease type X | Uncertain significance (Aug 22, 2022) | ||
7-44064832-C-A | Glycogen storage disease type X | Uncertain significance (Jul 21, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PGAM2 | protein_coding | protein_coding | ENST00000297283 | 3 | 2861 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.36e-7 | 0.118 | 125574 | 1 | 172 | 125747 | 0.000688 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.667 | 180 | 157 | 1.15 | 0.0000105 | 1647 |
Missense in Polyphen | 78 | 68.633 | 1.1365 | 705 | ||
Synonymous | -0.651 | 70 | 63.4 | 1.10 | 0.00000432 | 500 |
Loss of Function | -0.287 | 10 | 9.07 | 1.10 | 3.97e-7 | 106 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00789 | 0.00785 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.0000463 | 0.0000462 |
European (Non-Finnish) | 0.000204 | 0.000202 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.000294 | 0.000294 |
Other | 0.000652 | 0.000652 |
dbNSFP
Source:
- Function
- FUNCTION: Interconversion of 3- and 2-phosphoglycerate with 2,3- bisphosphoglycerate as the primer of the reaction. Can also catalyze the reaction of EC 5.4.2.4 (synthase), but with a reduced activity.;
- Pathway
- Glycolysis / Gluconeogenesis - Homo sapiens (human);Central carbon metabolism in cancer - Homo sapiens (human);Glucagon signaling pathway - Homo sapiens (human);Glycine, serine and threonine metabolism - Homo sapiens (human);Warburg Effect;Glycolysis;Glycogenosis, Type VII. Tarui disease;Gluconeogenesis;Glycogenosis, Type IA. Von gierke disease;Glycogenosis, Type IC;Fanconi-bickel syndrome;Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease;Triosephosphate isomerase;Fructose-1,6-diphosphatase deficiency;Phosphoenolpyruvate carboxykinase deficiency 1 (PEPCK1);Glycogenosis, Type IB;Glycolysis and Gluconeogenesis;Metabolism of carbohydrates;Glycolysis Gluconeogenesis;Metabolism;Rapoport-Luebering glycolytic shunt;Glycolysis;gluconeogenesis;glycolysis;superpathway of conversion of glucose to acetyl CoA and entry into the TCA cycle;Gluconeogenesis;Glucose metabolism
(Consensus)
Recessive Scores
- pRec
- 0.215
Intolerance Scores
- loftool
- 0.468
- rvis_EVS
- -0.51
- rvis_percentile_EVS
- 21.56
Haploinsufficiency Scores
- pHI
- 0.703
- hipred
- Y
- hipred_score
- 0.665
- ghis
- 0.445
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.997
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Pgam2
- Phenotype
Zebrafish Information Network
- Gene name
- pgam2
- Affected structure
- fast muscle cell
- Phenotype tag
- abnormal
- Phenotype quality
- decreased diameter
Gene ontology
- Biological process
- gluconeogenesis;glycolytic process;striated muscle contraction;Notch signaling pathway;spermatogenesis;response to mercury ion;canonical glycolysis
- Cellular component
- nucleus;cytosol;extracellular exosome
- Molecular function
- bisphosphoglycerate mutase activity;phosphoglycerate mutase activity;hydrolase activity;2,3-bisphosphoglycerate-dependent phosphoglycerate mutase activity;cofactor binding